Generic selectors
Exact matches only
Search in title
Search in content
Filter by Categories
2008
2009
2010
Announcements
Articles
Articles and Publications
Campaign
Case Studies
Charge Capture and Pricing
Coding Integrity
Company
Consulting
Craneware Insights Articles
Education
Home
Journey
News & Events
Opportunities
Other
post
Press Releases
Products
Services
Testimonial
Trade Shows
Uncategorized
Uncategorized
Upcoming Events
Value Cycle
Webinars
White Papers

Has the AMA created new CPT codes to report for COVID-19 vaccines and their administration?

Yes. However, before providing additional detail surrounding these new codes it is extremely important to point out that these codes are not yet effective. Per the AMA, the codes noted below will become effective only when the specific vaccine product has been granted either full approval or an emergency use authorization (EUA) by the FDA. There is no timeline for when this may occur for either vaccine product, however we will be sure to provide an update as soon as an announcement is made by the FDA. Below we have noted the new vaccine product and administration codes along with their long descriptions for your convenience.

New vaccine product codes:


91300: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use


91301: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use


New administration codes:


0001A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose


0002A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose


0011A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose


0012A: Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose

CPT 91300 will be used to report Pfizer-BioNTech’s COVID vaccine product. CPT codes 0001A (first dose) and 0002A (second dose) will be used to report the administration of the Pfizer-BioNTech COVID vaccine.

CPT 91301 will be used to report Moderna’s COVID vaccine product. CPTs 0011A (first dose) and 0012A (second dose) will be used to report the administration of the Moderna COVID vaccine.

Per the AMA, administration codes 0001A-0012A include vaccine risk/benefit counseling when performed.

AMA CPT Assistant Article – Vaccine Coding Development for COVID-19:
https://www.ama-assn.org/system/files/2020-11/cpt-assistant-guide-covid-vaccine-coding-2020.pdf